Evidence map›Paper›PMID 36774504›Full record

ReviewJournal of translational medicine2023

Liquid biopsies: the future of cancer early detection.

Siobhan Connal, James M Cameron, Alexandra Sala, Paul M Brennan, David S Palmer, Joshua D Palmer, Haley Perlow, Matthew J Baker

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Liquid biopsy and health-related quality of life in cancers: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Building Disease Models for Endometriosis: iPSCs as Game-Changers.International journal of molecular sciences · 2026
    Review
  19. Article
  20. Review

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siobhan ConnalDxcover Ltd., Royal College Building, 204 George Street, Glasgow, G1 1XW, UK.
James M CameronDxcover Ltd., Royal College Building, 204 George Street, Glasgow, G1 1XW, UK.
Alexandra SalaDxcover Ltd., Royal College Building, 204 George Street, Glasgow, G1 1XW, UK.
Paul M BrennanTranslational Neurosurgery, Centre for Clinical Brain Sciences, 49 Little France Crescent, University of Edinburgh, Edinburgh, EH16 4BS, UK.
David S PalmerDxcover Ltd., Royal College Building, 204 George Street, Glasgow, G1 1XW, UK.
Joshua D PalmerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Haley PerlowDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Matthew J BakerDxcover Ltd., Royal College Building, 204 George Street, Glasgow, G1 1XW, UK. matthew.baker@dxcover.com.

Funding

Cancer Research UK A28345
6 · The paper itself

Abstract

Cancer is a worldwide pandemic. The burden it imposes grows steadily on a global scale causing emotional, physical, and financial strains on individuals, families, and health care systems. Despite being the second leading cause of death worldwide, many cancers do not have screening programs and many people with a high risk of developing cancer fail to follow the advised medical screening regime due to the nature of the available screening tests and other challenges with compliance. Moreover, many liquid biopsy strategies being developed for early detection of cancer lack the sensitivity required to detect early-stage cancers. Early detection is key for improved quality of life, survival, and to reduce the financial burden of cancer treatments which are greater at later stage detection. This review examines the current liquid biopsy market, focusing in particular on the strengths and drawbacks of techniques in achieving early cancer detection. We explore the clinical utility of liquid biopsy technologies for the earlier detection of solid cancers, with a focus on how a combination of various spectroscopic and -omic methodologies may pave the way for more efficient cancer diagnostics.

Indexed as

Early Detection of CancerNeoplasmsForecastingHumansLiquid BiopsyQuality of LifeCancerDiagnosticsEarly detectionLiquid biopsyMulti-cancer

Identifiers

PMID36774504
PMCPMC9922467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.